News ArticleAurobindo Pharma Reappoints Mangalam Ramasubramanian Kumar as Independent Director for Five-Year Term Starting April 1, 2027
Mr. Kumar’s re-appointment is pending member approval through postal ballot as his current term concludes March 31, 2027
Aurobindo Pharma announced the re-appointment of Mr. Mangalam Ramasubramanian Kumar as a Non-executive and Independent Director for a second term of five years, effective April 1, 2027, subject to member approval via postal ballot. His first term ends on March 31, 2027. He holds an extensive career in life insurance and finance sectors, currently serving as Non-executive Chairman of Bank of India and director on multiple boards.
Aurobindo Pharma Limited
Change in Management
Aurobindo Pharma Limited's board approved the re-appointment of Mr. Mangalam Ramasubramanian Kumar as a Non-executive and Independent Director for a second five-year term effective April 1, 2027, pending shareholder approval via postal ballot.
The re-appointment was recommended by the Nomination and Remuneration Committee and announced on November 4, 2026, during the board meeting held from 4:15 p.m. to 6:00 p.m.
Mr. Kumar's first term as an Independent Director completes on March 31, 2027. The new term is also for five years, and he will not be liable to retire by rotation.
He will receive sitting fees for attending board and committee meetings along with commission as applicable.
Mr. Kumar is a Science graduate from the University of Madras with extensive experience, including serving as Chairman of LIC of India from March 2019 to March 2023 and holding executive roles in various zones and departments at LIC.
Currently, he holds directorships including Non-executive Chairman of Bank of India and director positions at Cholamandalam Investment and Finance Company Limited, as well as Aurobindo Pharma USA Inc.
Highlights
- Re-appointment effective April 1, 2027, for five years pending member approval.
- First term ending March 31, 2027, completed without incident.
- Mr. Kumar is not related to any director or key managerial personnel of Aurobindo Pharma.
- He has an extensive leadership background with LIC of India and banking institutions.
- Board meeting approving re-appointment conducted on November 4, 2026, from 4:15 p.m. to 6:00 p.m.
Key Data Snapshot
What happened
- Aurobindo Pharma’s board approved the re-appointment of Mr. Mangalam Ramasubramanian Kumar as Non-executive and Independent Director starting April 1, 2027.
- This re-appointment is for a five-year term, contingent on approval from members by postal ballot.
- His initial term ends on March 31, 2027.
Key details
- Mr. Kumar will receive sitting fees for board and committee meetings and applicable commission.
- He is not related to any director or key managerial personnel of Aurobindo Pharma, ensuring independence.
- The re-appointment was recommended by the Nomination and Remuneration Committee.
Background and context
- Mr. Kumar is a Science graduate from University of Madras with over three and a half decades experience in life insurance and financial services.
- He served as Chairman of LIC of India from March 2019 to March 2023, heading several zones and departments during his tenure.
- He has held leadership roles including Non-executive Chairman positions at various LIC subsidiaries and IDBI Bank, as well as board directorships in Indian and international firms.
- Currently, he serves as Non-executive Chairman of Bank of India and director on the boards of Cholamandalam Investment and Finance Company Limited and Aurobindo Pharma USA Inc.
Regulatory and governance context
- Mr. Kumar is not debarred from holding office under any SEBI order or similar authority.
- The re-appointment is subject to shareholders’ approval by a special resolution via postal ballot.
- Applicable disclosures comply with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Highlights
- Re-appointment effective April 1, 2027, for five years pending member approval.
- First term ending March 31, 2027, completed without incident.
- Mr. Kumar is not related to any director or key managerial personnel of Aurobindo Pharma.
- He has an extensive leadership background with LIC of India and banking institutions.
- Board meeting approving re-appointment conducted on November 4, 2026, from 4:15 p.m. to 6:00 p.m.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Change in Management
View allLatest corporate announcements and market updates in Change in Management.
Sundaram Finance Appoints Mr. Sriram Viji as Non-Executive Non-Independent Director
Sundaram Finance Limited has named Mr. Sriram Viji as an Additional Director on its Board in the capacity of Non-Executive Non-Independent Director, with the appointment effective November 4, 2026. This decision follows the recommendation from the Nomination, Compensation and Remuneration Committee and awaits shareholder approval.
Read Full Story
Sundaram Finance Appoints R. Venkatraman as Chairman After S. Viji Steps Down
Sundaram Finance Limited announced the resignation of Mr. S. Viji as Chairman and Non-Executive Director effective at the close of the Board Meeting on November 4, 2026. The Board has appointed Independent Director Mr. R. Venkatraman as the new Chairman.
Read Full Story
Axis Bank Gains RBI Nod to Reappoint Munish Sharda as Executive Director Until 2030
Axis Bank announced that the Reserve Bank of India has approved the reappointment of Munish Sharda as Whole-Time Director, designated Executive Director, for a period of three years commencing February 27, 2027, extending through February 26, 2030.
Read Full Story
